Jean–Marc Phelip

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Colon cancer in France: evidence for improvement in management and survival

Corinne Faivre‐Finn, A-M Bouvier-Benhamiche, Jean–Marc Phelip et al. · Gut · 2002 · 295 citations · Full text

Medicine, Oncology, Surgery +17

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

Xavier Roblin, Hubert Marotte, Melanie Rinaudo et al. · Clinical Gastroenterology and Hepatology · 2013 · 276 citations

Medicine, Immunology, Pharmacokinetics +16

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

Stéphane Paul, Émilie Del Tedesco, Hubert Marotte et al. · Inflammatory Bowel Diseases · 2013 · 220 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17